MICM
TPTX

Matthews International Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Matthews International Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38,605
Closed -$1.84M – 42
2021
Q4 		$1.84M Sell
38,605
-97,295
-72% -$4.35M 0.19% 27
2021
Q3 		$9.03M Hold
135,900
– – 0.55% 26
2021
Q2 		$10.6M Hold
135,900
– – 0.44% 33
2021
Q1 		$12.9M Buy
135,900
+66,100
+95% +$7.86M 0.54% 33
2020
Q4 		$8.51M Sell
69,800
-48,200
-41% -$5.28M 0.45% 26
2020
Q3 		$10.3M Hold
118,000
– – 0.69% 22
2020
Q2 		$7.62M Hold
118,000
– – 0.59% 23
2020
Q1 		$5.27M Hold
118,000
– – 0.34% 26
2019
Q4 		$7.35M Hold
118,000
– – 0.35% 24
2019
Q3 		$4.44M Buy
+118,000
New +$5.14M 0.2% 30

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Matthews International Capital Management's TPTX Position: Q1 2022 in Review

Matthews International Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 38,605 shares — an estimated $1.84M sold.

Matthews International Capital Management first reported a position in TPTX in Q3 2019 and held it in 10 quarters. The position peaked at $12.9M in Q1 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Matthews International Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Matthews International Capital Management sold 38,605 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.84M.
  • Matthews International Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
  • Matthews International Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $12.9M in Q1 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Matthews International Capital Management's 13F filing for Q1 2022, filed 5 May 2022.